Indian firm SS Innovations International, Inc. (SSII), a developer of innovative surgical robotic technologies dedicated to making world-class robotic surgery affordable and accessible to a global population, has announced that its SSi Mantra Surgical Robotic System has received regulatory approval from the Indonesian Ministry of Health for clinical use in the Republic of Indonesia.

With more than 279 million people, Indonesia is the world’s fourth-most-populous country. However, robotic surgery has been slow to reach the island nation. Indonesia’s Bunda Hospital in Jakarta acquired its first robotic surgical system in 2012 and has only completed about 700 surgeries in the past 12 years.

“With the entry of the SSi Mantra to the Indonesian market, we believe that we can be instrumental in increasing access to and decreasing costs of robotic surgery options,” said Dr Sudhir Srivastava, SS Innovation’s Chairman and CEO. “We look forward to broadening surgical horizons for Indonesians and continuing to expand our innovative surgical services and options across the globe.”

Last month, SS Innovations announced that it had completed 100 robotic cardiac surgery cases in just over a year, utilising the SSi Mantra Surgical Robotic System. It is the first surgical robotic system made in India, and one of the only systems in the world designed to be cost-effective with broad-spectrum surgical applications. The SSi Mantra is clinically validated in more than 70 different types of surgical procedures. SS Innovations has commenced the regulatory approval process in the United States and the European Union and anticipates receiving US FDA approval to market and CE Mark approval in 2025.